Salix, Cedars-Sinai go with their gut, strike partnership

Listen to this article

Bridgewater’s Salix Pharmaceuticals and Cedars-Sinai Medical Center have partnered to develop research for the treatment of gastrointestinal disorders, with a start projected for the third quarter.Bridgewater’s Salix Pharmaceuticals and Cedars-Sinai Medical Center have partnered to develop research for the treatment of gastrointestinal disorders, with a start projected for the third quarter.

Under the agreement, the lab of Dr. Mark Pimentel, executive director of the Medically Associated Science and Technology Program at Cedars-Sinai, will research micro-organisms in the gut, and Salix – a specialty pharmaceutical company whose products are geared toward the prevention and treatment of GI disorders – will have the option to acquire any therapies discovered from the research.

“The gut microbiome represents a great deal of promise and opportunity for disruptive change in gastroenterology,” said Salix President Mark McKenna in a statement.

Salix is a wholly owned subsidiary of Bausch Health Companies Inc.